A cannabinoid drug company has opted to undertake its trials in America due to the complexities of the UK’s licensing regime.
The Canadian Federal government’s failure to facilitate research into the potential health issues associated with cannabis consumption. According to Toronto-based
UK-based Apollon Formularies and Global Hemp Group (GHG) have signed a Letter of Intent GHG will acquire the exclusive perpetual
The company has received Ethics Approval from Bellberry Human Research Ethics Committee in Australia.
The application has been submitted in preparation for a review.
The site will be opened by UK cannabis company Eden Pharma.
The paper explores what Cellular Goods refers to as the ‘5 A’s of cannabinoid skincare’.
A new study concludes that conventional pharmaceutical manufacturers may benefit from investing in cannabis markets rather than lobbying against them.
MGC Pharma has carried out a doubleblind, randomised, placebo controlled clinical study investigating the impact of its epilepsy treatment on driving performance.
A team of researchers has used firefly genes to understand cannabis biology.
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
